Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Venous Thromboembolism | 4 | 2025 | 154 | 2.180 |
Why?
|
| Wounds and Injuries | 5 | 2025 | 250 | 1.280 |
Why?
|
| Heart Arrest | 1 | 2022 | 177 | 0.630 |
Why?
|
| Mesentery | 1 | 2018 | 17 | 0.550 |
Why?
|
| Multidetector Computed Tomography | 1 | 2018 | 22 | 0.540 |
Why?
|
| Intestines | 1 | 2018 | 184 | 0.490 |
Why?
|
| Benzodiazepines | 3 | 2025 | 107 | 0.470 |
Why?
|
| Cannabinoids | 2 | 2025 | 41 | 0.430 |
Why?
|
| Trauma Centers | 6 | 2025 | 130 | 0.410 |
Why?
|
| Accidental Falls | 2 | 2025 | 130 | 0.410 |
Why?
|
| Laparotomy | 2 | 2017 | 56 | 0.370 |
Why?
|
| Intra-Abdominal Hypertension | 1 | 2011 | 2 | 0.360 |
Why?
|
| Intracranial Hypertension | 1 | 2011 | 9 | 0.350 |
Why?
|
| Ethanol | 2 | 2025 | 333 | 0.350 |
Why?
|
| Risk Assessment | 3 | 2025 | 2113 | 0.350 |
Why?
|
| Multiple Trauma | 1 | 2011 | 30 | 0.350 |
Why?
|
| Retrospective Studies | 8 | 2025 | 6949 | 0.340 |
Why?
|
| Decompression, Surgical | 1 | 2011 | 71 | 0.340 |
Why?
|
| Analgesics, Opioid | 2 | 2025 | 530 | 0.310 |
Why?
|
| Brain Injuries | 1 | 2011 | 141 | 0.310 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2008 | 175 | 0.280 |
Why?
|
| Liver Neoplasms | 2 | 2008 | 308 | 0.260 |
Why?
|
| Anticoagulants | 2 | 2021 | 529 | 0.240 |
Why?
|
| Risk Factors | 4 | 2025 | 5466 | 0.230 |
Why?
|
| Humans | 18 | 2025 | 65657 | 0.220 |
Why?
|
| ROC Curve | 1 | 2025 | 294 | 0.220 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2023 | 4 | 0.200 |
Why?
|
| Adult | 7 | 2025 | 17511 | 0.190 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2023 | 126 | 0.180 |
Why?
|
| Computed Tomography Angiography | 1 | 2022 | 143 | 0.170 |
Why?
|
| Enoxaparin | 1 | 2021 | 19 | 0.170 |
Why?
|
| Pandemics | 2 | 2022 | 691 | 0.160 |
Why?
|
| Alcoholism | 1 | 2023 | 329 | 0.150 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2020 | 116 | 0.140 |
Why?
|
| Spleen | 1 | 2020 | 476 | 0.140 |
Why?
|
| Aged | 5 | 2025 | 15090 | 0.140 |
Why?
|
| Female | 9 | 2025 | 34312 | 0.130 |
Why?
|
| Thoracic Injuries | 1 | 2018 | 46 | 0.130 |
Why?
|
| Middle Aged | 5 | 2025 | 18440 | 0.130 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1715 | 0.130 |
Why?
|
| Abdominal Injuries | 1 | 2017 | 32 | 0.120 |
Why?
|
| Wounds, Gunshot | 1 | 2017 | 48 | 0.120 |
Why?
|
| Adolescent | 2 | 2021 | 6350 | 0.120 |
Why?
|
| Male | 7 | 2025 | 31299 | 0.120 |
Why?
|
| Liver | 1 | 2020 | 874 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 273 | 0.110 |
Why?
|
| New England | 3 | 2021 | 271 | 0.110 |
Why?
|
| Injury Severity Score | 2 | 2025 | 117 | 0.090 |
Why?
|
| Hematoma, Subdural, Intracranial | 1 | 2011 | 2 | 0.090 |
Why?
|
| Mannitol | 1 | 2011 | 15 | 0.090 |
Why?
|
| APACHE | 1 | 2011 | 42 | 0.090 |
Why?
|
| Glasgow Outcome Scale | 1 | 2011 | 17 | 0.090 |
Why?
|
| Intracranial Pressure | 1 | 2011 | 19 | 0.090 |
Why?
|
| Glasgow Coma Scale | 1 | 2011 | 48 | 0.090 |
Why?
|
| Brain Edema | 1 | 2011 | 29 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 710 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 5657 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 106 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 372 | 0.080 |
Why?
|
| Accidents, Traffic | 1 | 2011 | 140 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 230 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 294 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2008 | 128 | 0.060 |
Why?
|
| Oncolytic Virotherapy | 1 | 2007 | 9 | 0.060 |
Why?
|
| Phenobarbital | 2 | 2023 | 13 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 198 | 0.060 |
Why?
|
| Herpesvirus 1, Human | 1 | 2007 | 83 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 231 | 0.060 |
Why?
|
| Virus Replication | 1 | 2007 | 323 | 0.060 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2005 | 14 | 0.050 |
Why?
|
| Toes | 1 | 2005 | 14 | 0.050 |
Why?
|
| Face | 1 | 2005 | 36 | 0.050 |
Why?
|
| Fingers | 1 | 2005 | 49 | 0.050 |
Why?
|
| Substance Abuse Detection | 1 | 2024 | 39 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2005 | 104 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 1662 | 0.050 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2005 | 155 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2007 | 888 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2005 | 224 | 0.050 |
Why?
|
| United States | 2 | 2024 | 8166 | 0.050 |
Why?
|
| Seizures | 1 | 2023 | 141 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 40 | 0.040 |
Why?
|
| Factor Xa Inhibitors | 1 | 2021 | 38 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1453 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 416 | 0.030 |
Why?
|
| Neoplasms | 1 | 2007 | 1376 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3329 | 0.020 |
Why?
|
| Cetuximab | 1 | 2008 | 8 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 19 | 0.020 |
Why?
|
| Vimentin | 1 | 2008 | 19 | 0.020 |
Why?
|
| Quinazolines | 1 | 2008 | 21 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2008 | 23 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2008 | 30 | 0.020 |
Why?
|
| Mesoderm | 1 | 2008 | 89 | 0.020 |
Why?
|
| Cadherins | 1 | 2008 | 90 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 70 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 391 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 216 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4855 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 869 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 254 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2008 | 414 | 0.010 |
Why?
|
| Facies | 1 | 2005 | 10 | 0.010 |
Why?
|
| Carbamazepine | 1 | 2005 | 10 | 0.010 |
Why?
|
| Phenytoin | 1 | 2005 | 15 | 0.010 |
Why?
|
| Intelligence Tests | 1 | 2005 | 26 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 1573 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 875 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 2496 | 0.010 |
Why?
|
| Animals | 2 | 2008 | 21468 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 2393 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2007 | 5820 | 0.010 |
Why?
|
| Child | 1 | 2005 | 4635 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 11175 | 0.010 |
Why?
|